Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid.

ABSTRACT:

Background

Early and accurate detection and staging is critical to managing Alzheimer's disease (AD) and supporting clinical trials. Cerebrospinal fluid (CSF) biomarkers for amyloid-β peptides, tau species, and various neurodegenerative and inflammatory analytes are leading the way in this regard, yet there is room for improved sensitivity and specificity. In particular tau is known to be present in many different fragments, conformations, and post-translationally modified forms. While the exact tau species that might best reflect AD pathology is unknown, a growing body of evidence suggests that forms with high levels of phosphorylation in the mid-region may be especially enriched in AD.

Objective

Develop an assay for measuring p217tau in CSF.

Methods

Here we describe

SUBMITTER: Triana-Baltzer G 

PROVIDER: S-EPMC7683057 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature